To be clear, I don't think Novartis would necessarily be considering a TO offer, it just becomes a more attractive option now that the share price is low if there is promise in rem-L for all cause ARDS. They were smart to include the futility clause in their contract, that's a good example of covering all bases on trials and trial results.
I doubt they will publish the full data, but if they do I'll definitely be sniffing around in it for some answers and clues.
USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse, page-53
-
- There are more pages in this discussion • 259 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.003(0.21%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.20 | $1.15 | $2.225M | 1.901M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 15843 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 28914 | 16 |
View Market Depth
| Last trade - 13.05pm 16/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |